Safety and Efficacy of MT-4666

Summary

The objective of this study is to evaluate the safety and efficacy as assessed by the Alzheimers Disease Assessment Scale-cognitive subscale 13-item (ADAS-cog-13) of two doses of MT-4666 or placebo administered daily for 24 weeks to subjects with mild to moderate Alzheimer's disease.

Timeline

Start

2012-11

Primary completion

2015-06

Completion

2015-07

Drugs

Indications